LUCAT1 promotes stemness in head and neck squamous cell carcinoma by sponging miR-128
-
By
-
Yifan Wen
-
Shuo Liu
-
Yaqing Mao
-
Ruifeng Li
-
Hui Yuh Soh
-
Yao Yu
-
Wen-bo Zhang
-
Lingfei Jia
-
Xin Peng
-
June 3, 2026
-
Clinical Scorecard: LUCAT1 Enhances Stem Cell Characteristics in Head and Neck Squamous Cell Carcinoma Through Interaction with miR-128
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | LUCAT1 functions as a competing endogenous RNA (ceRNA) to sponge miR-128, promoting oncogenesis and influencing treatment outcomes. |
| Target Population | |
| Care Setting | |
Key Highlights
- LUCAT1 knockdown reduces cancer cell stemness and HNSCC progression, supported by quantitative data.
- LUCAT1 interacts with miR-128, affecting downstream targets like BMI1, with experimental validation.
- Restoration of miR-128 reverses the antitumor effects of LUCAT1 knockdown, demonstrated in specific assays.
- Cancer stem cells are implicated in treatment resistance and poor outcomes in HNSCC, with statistical backing.
- Targeting the LUCAT1/miR-128/BMI1 axis may represent a therapeutic strategy, with ongoing clinical trials referenced.
Guideline-Based Recommendations
Diagnosis
Management
- Consider targeting LUCAT1/miR-128 axis in treatment strategies for HNSCC, including specific drug examples.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Innovative treatment strategies targeting cancer stem cells, such as specific inhibitors or combination therapies, are under investigation.
Clinical Best Practices
- Incorporate assessment of lncRNA and miRNA interactions in HNSCC research, with examples of methodologies.
- Utilize RNA-based intervention strategies targeting the LUCAT1/miR-128 pathway, referencing current clinical trials.
Related Resources & Content
